Kraig Biocraft Laboratories (KBLB) Common Equity (2010 - 2025)

Kraig Biocraft Laboratories (KBLB) has 16 years of Common Equity data on file, last reported at -$8.0 million in Q4 2025.

• For the quarter ending Q4 2025, Common Equity rose 1.85% year-over-year to -$8.0 million; the trailing twelve-month figure through Dec 2025 stood at -$8.0 million (up 1.85% YoY), and the FY2025 full-year result was -$8.0 million, up 1.85% from the prior year.
• Common Equity fell to -$8.0 million in Q4 2025, from -$8.0 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of -$3.5 million in Q4 2022 to a low of -$8.5 million in Q1 2025.
• A 5-year average of -$6.0 million and a median of -$5.8 million in 2021 frame the typical range for Common Equity.
• Across the five-year window, Common Equity soared 40.36% in 2022 and sank 62.05% in 2023, its largest moves.
• Tracing KBLB's Common Equity over 5 years: stood at -$5.3 million in 2021, then soared by 33.5% to -$3.5 million in 2022, then plunged by 62.05% to -$5.7 million in 2023, then slumped by 42.8% to -$8.1 million in 2024, then climbed by 1.85% to -$8.0 million in 2025.
• Business Quant data shows KBLB's Common Equity at -$8.0 million in Q4 2025, -$8.0 million in Q3 2025, and -$8.5 million in Q2 2025.